HAE logo

HAEMONETICS CORP/MASS

HAENYSE
πŸ† #1256 by market capEarnings Nov 4US Equity
$129.41β–² $9.80 (+7.57%)
Simulated price
1hβ€”
24hβ–² 7.6%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$3.97B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.4%
Slowing
πŸ“ŠGross Margin
59.1%
Healthy
πŸ’΅FCF Margin
18.1%
Healthy
βš–οΈP/S Ratio
2.9x
Cheap
Otter Score
63
Fair
No chart data available for HAE.

Trading Snapshot

Day Range
$127.45 – $130.12
52-Week Range
$47.32 – $88.59
Volume
$1.69B
Avg Volume
$1.55B
Shares Outstanding
45.5M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$1.33B
Last Q Revenue
$339M
P/E Ratio
40.9
P/S Ratio
2.9x
EPS (TTM)
$2.05
Dividend Yield
β€”

Why Investors Own HAE

  • βœ“High-growth profile β€” revenue up +14.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 64% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.33Bβ–² +17.4% YoY
Gross Margin (TTM)
63.6%β–Ό βˆ’0.1% YoY
Operating Income (TTM)
$133Mβ–² +17.4% YoY
Free Cash Flow (TTM)
$215Mβ–² +17.4% YoY

About HAEMONETICS CORP/MASS

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
63/100

Analyst Price Target

β“˜
Average Target
$126.32
β–Ό βˆ’2.4% Downside
High Target$154.48
Low Target$96.98
Based on 19 analysts

Latest News & Updates